Targeting nocturnal hypertension in type 2 diabetes mellitus

Hypertension

Volumn 64, Issue 5, 2014, Pages 1080-1087

  Rossen, Niklas Blach ^a,b   Knudsen, Søren Tang ^b   Fleischer, Jesper ^b   Hvas, Anne Mette ^b   Ebbehøj, Eva ^b   Poulsen, Per Løgstrup ^b   Hansen, Klavs Würgler ^a  

^a SILKEBORG REGIONAL HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Ambulatory; Blood pressure monitoring; Chronotherapy; Diabetes mellitus; Hypertension; Type 2

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOXONIDINE; ORAL ANTIDIABETIC AGENT; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BEDTIME DOSAGE; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; NATRIURESIS; NOCTURIA; NOCTURNAL HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; POPULATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SLEEP TIME; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TIME TO TREATMENT; URINALYSIS; URINARY EXCRETION; URINE OSMOLALITY; BLOOD PRESSURE; CIRCADIAN RHYTHM; COMORBIDITY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; URINE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CIRCADIAN RHYTHM; COMORBIDITY; CREATININE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SODIUM; TREATMENT OUTCOME;

EID: 84922394408     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03958     Document Type: Article

References (38)

1. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546.
2. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-161.
3. Hermida RC, Ayala DE, Mojón A, Fernández JR. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens. 2012;25:325-334.
4. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension. 2005;45:240-245.
5. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-1783.
6. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011;57:3-10.
7. Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. Administration-time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010;15:173-180.
8. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:1629-1651.
9. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(Suppl 1):S11-S63.
10. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-2222.
11. Tofé Povedano S, García De La Villa B. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich). 2009;11:426-431.
12. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34:1270-1276.
13. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension. 2006;47:149-154.
14. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401-1406.
15. Ejskjaer N, Fleischer J, Fleischer J, Jacobsen PE, Poulsen PL, Nygaard H. A Pocket-size device to detect autonomic neuropathy. J Diabetes Sci Technol. 2008;2:692-696.
16. Charles M, Fleischer J, Witte DR, Ejskjaer N, Borch-Johnsen K, Lauritzen T, Sandbaek A. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screendetected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia. 2013;56:101-108.
17. Rossen NB, Hansen KW. Comment on: Hermida et al. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011;34:1270-1276. Diabetes Care. 2011;34:e184, author reply e185.
18. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Response to comment on: Hermida et al. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. diabetes care 2011;34: 1270-1276. Diabetes Care. 2011;34:e185.
19. Li Y, Thijs L, Hansen TW, et al; International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension. 2010;55:1040-1048.
20. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, Ambrosio G, Reboldi G. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension. 2012;60:34-42.
21. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-140.
22. Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA. 2005;294:1799-1809.
23. Hermida RC, Calvo C, Ayala DE, López JE, Fernández JR, Mojón A, Domínguez MJ, Covelo M. Seasonal variation of fibrinogen in dipper and nondipper hypertensive patients. Circulation. 2003;108:1101-1106.
24. Tsioufis C, Syrseloudis D, Dimitriadis K, Thomopoulos C, Tsiachris D, Pavlidis P, Selima M, Kallikazaros I, Stefanadis C. Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. J Hum Hypertens. 2008;22:501-508.
25. Syrseloudis D, Tsioufis C, Andrikou I, Mazaraki A, Thomopoulos C, Mihas C, Papaioannou T, Tatsis I, Tsiamis E, Stefanadis C. Association of nighttime hypertension with central arterial stiffness and urinary albumin excretion in dipper hypertensive subjects. Hypertens Res. 2011;34:120-125.
26. Hermida RC, Calvo C, Ayala DE, López JE. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension. 2005;46:960-968.
27. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-2081.
28. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30-48.
29. Mitchell TH, Nolan B, Henry M, Cronin C, Baker H, Greely G. Microalbuminuria in patients with non-insulin-dependent diabetes mellitus relates to nocturnal systolic blood pressure. Am J Med. 1997;102:531-535.
30. Knudsen ST, Poulsen PL, Hansen KW, Ebbehøj E, Bek T, Mogensen CE. Pulse pressure and diurnal blood pressure variation: association with micro- and macrovascular complications in type 2 diabetes. Am J Hypertens. 2002;15:244-250.
31. Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia. 2010;53:49-57.
32. Kario K, Hoshide S, Shimizu M, Yano Y, Eguchi K, Ishikawa J, Ishikawa S, Shimada K. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2010;28:1574-1583.
33. Laugesen E, Poulsen PL. The J-curve limbo: how low can you go? J Clin Endocrinol Metab. 2013;98:3588-3591.
34. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
35. O'Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:697-701.
36. Kikuya M, Hansen TW, Thijs L, Björklund-Bodegard K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA; International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. 2007;115:2145-2152.
37. Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR. Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens. 2013;31:2176-2186.
38. Hermida RC, Ayala DE, Mojón A, Fernández JR. Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk. Chronobiol Int. 2013;30:328-339.